Astral shares are up 7.4% at the moment.

Astral Q1

Net Profit At Rs 120 Cr Vs CNBC-TV18 Poll Of Rs 116 Cr

Revenue At Rs 1,578 Cr Vs CNBC-TV18 Poll Of Rs 1,588 Cr

EBITDA At Rs 231 Cr Vs CNBC-TV18 Poll Of Rs 231 Cr

Margin At 14.7% Vs CNBC-TV18 Poll Of 14.6%

Net Profit Up 51.8% At Rs 120 Cr Vs Rs 79 Cr (YoY)

Revenue Up 15.9% At Rs 1,578 Cr Vs Rs 1,361 Cr (YoY)

EBITDA Up 23% At Rs 231 Cr Vs Rs 188 Cr (YoY)

Margin At 14.7% Vs 13.8% (YoY)

Suneeta Reddy, Apollo Hospitals On CNBC-TV18:

Access Is Guaranteed Through Insurance For Patients Resulting In Expansion

Looking At 5,000 Beds In New Cities, Will Look To Grow Beds In The North

Will Fund Capex Via Internal Cash Accruals

As A Nation We Are Underserved, Need 1 Lk Beds

See Convergence Of Care In The Hospital Space

Patients Going Abroad Now Access Hospital Care In India

Need To Have A Dialogue With The Govt On Price Cap Recos

Have A Meeting Lined Up With The Govt On Healthcare Recommendations

Digital Biz Loss Will Be Wiped Away Next Quarter

Looking At How Apollo Can Enhance Indraprastha Hospital

Looking At Improving Margin To 25% In Hospital Biz

The stock is up 4.5% at the moment, reacting to its first quarter results.

It reported positive sales growth after seven quarters while its EBITDA and PAT loss continued.

Dr Adil Agarwal, CEO, Dr Agarwal’s Health On CNBC-TV18:

Expect Temasek & TPG To Hold On To Remaining Shares As They Are Long Term Investors

Promoters Would Like To Increase Stake

Would Like To Be North Of 40% Promoter Holding

Did Not Buy Stake In This Round, Negotiations Were Between Bankers, TPG & Temasek

Parliamentary Committee Recommendations Won’t Impact Co As Dr Agarwal’s Is A Day-Care Operation

Co Undertakes Certain Number Of Surgeries Free Of Cost

Lenskart Solutions shares are up over 6.5% at the moment, reacting to their first quarter earnings

CLSA on Astral;

Hold, Target Price Rs 1,490
Resilient demand and channel inventory restocking has led to a strong 2Q start for Astral’s piping business (40% growth in July).
1Q was largely in line with flat volume growth (versus the industry down 10% YoY) driven by sharp channel destocking due to volatile PVC prices.

Jefferies on GMR Airports:

Buy, Target Prie Rs 125
1Q EBITDA at Rs14.5bn (est: Rs14.7bn), was higher 11% YoY.
1Q Pax growth was at 1% YoY, impacted by Airlines led capacity cut weighing on traffic growth (DIAL at +7%, GHIAL -12% YoY).
1Q Non-Aero Revenues grew 12% YoY despite muted traffic growth.
Segment Margins were higher QoQ for Hyd Airport while lower QoQ for Delhi Airport.
Adj for forex, adj PAT at Rs880mn (est: Rs795mn).
Net Debt was unchanged QoQ.

Jefferies on Lenskart

Buy, Target Price raised to Rs 680
1QFY27 continues to build the story, with strong growth & sharp margin expansion.
Market creation remains a top priority, with supply, rather than demand, being a key constraint in India, evidenced by c70k daily eye tests
Co now plays at bottom end with a fully loaded Rs500 product, while a clear premiumization trend is visible.
Margin improvement in international should put a key investor concern to rest.
Meller could be the Ray-Ban of future!

HSBC on Lenskart:

Hold, Target Price Rs 575
8% beat on consensus EBITDA driven by International, India in line; India SSSG at 18% vs 24% in Q4FY26
India estimates unchanged, international performance drives upgrade in overall estimates: 6%/5% for FY27/FY28 EBITDA
Premium multiples of 45x/30x FY30 EV/EBITDA factor potential

CITI on Apollo Hospitals:

Buy, Target Price Rs 10,770
Apollo delivered another strong quarter (21/28% yoy growth in Revenue/EBITDA), 2-3% ahead of our estimates.
Key highlights:
1) Hospitals business witnessed a 22% yoy revenue growth with EBITDA expanding 20% yoy, after absorbing losses of Rs380m from newly commissioned units.
2) Ex of losses, like-for-like EBITDA (for existing units) improved 25% yoy.
3) HealthCo revenues grew by a strong 20% yoy, with EBITDA margins expanding 200bps driven by reduction in 24/7 costs
Co has announced four new hospitals (~1,200 beds) and now targets >5,800 beds addition over the next five years, providing strong visibility on medium-term earnings growth.

CLSA on HAL:

Outperform, Target Price Rs 5,481
PAT ahead on delivery of a higher numbers of engines, helicopters & treasury income, while margins expanded.
Its cash pile rose to US$4.9bn, up 21% YoY, on large advances and a conservative accounting policy of parking economic value add in balance sheet until delivery of platforms
See start of Mk 1A deliveries (2H) & visibility on the engine production deal as key catalysts.
HAL is cheapest pure-play defence stock despite a sector-leading position

Nomura on Tata Motors CV:

Upgrade to Buy, Target Price Rs 554
1Q EBITDA ahead of estimates; strong performance across segments
Margins to improve further with price hikes
CV outlook brighter now; raised FY27F MHCV demand growth to 8% y-y (from 5%)
Management commentary
Demand: 2QFY27E should see healthy double-digit MHCV growth.
EVs: Strong growth as TCO is reaching earlier, EV penetration has touched 10% in SCVs
Exports: Indonesia order should be delivered over FY27-28E
Costs: There is cost pressure ahead and price hike of 2.5% was taken in July. There are some supply constraints due to strong demand
IVECO: Deal to close by early Nov-2026E.

Welcome to CNBC-TV18’s LIVE Blog on Q1 Results. Watch this space for LIVE Updates on Q1 Results, management commentary, stock reactions, brokerage views and more.